AXPAXLI Phase 3 Data Shows Unmatched Durability in Wet AMD, NDA Submission on Track
summarizeSummary
Ocular Therapeutix announced additional positive Week 52 data from its SOL-1 Phase 3 trial for AXPAXLI in wet age-related macular degeneration (AMD). The new post-hoc analyses, presented at the Vit-Buckle Society Meeting, reinforced AXPAXLI's superior durability and sustained disease control, with subjects showing significantly lower risk of anatomic worsening compared to the control arm. The company highlighted a median time of 39 weeks to a clinically meaningful increase in Central Subfield Thickness (CSFT) from Week 8. This strong data significantly de-risks AXPAXLI's path to market, with the company reiterating it remains on track to submit its New Drug Application (NDA) based on SOL-1 alone, subject to planned FDA discussions. This update provides further confidence in the drug's potential approval and commercial success in the wet AMD market.
At the time of this announcement, OCUL was trading at $8.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.80 to $16.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.